Drugs / Ad5-105K
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06732583 | Nov 2025 → Aug 2026 overdue | tuberculosis | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-105K | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06732583 ↗ |
| Modality | Vaccine | “a Viral Vector-based Tuberculosis (TB) Vaccine Ad5-105K Against TB Disease” NCT06732583 ↗ |
| Route | Inhaled | “Nebulized Inhalation (IH) through mouth” NCT06732583 ↗ |